QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery - Seite 2
Key features of QIAGEN Biomedical KB-AI include:
- Massive scale: 640 million biomedical relationships curated from literature, patents, grants and other sources
- Causality: Over 6.4 million gene causal relationships, 1.99 million disease causal relationships and 1.16 million drug causal relationships
- Structured: Results are structured in an ontology for rapid querying and advanced analytics
- Timely: Updated quarterly to capture the most recent research and discoveries
QIAGEN continuously integrates AI technology in its QIAGEN Digital Insights portfolio. As recently as September 2023, it released an AI-driven enhancement to its market-leading QIAGEN Clinical Insight Interpret product capabilities.
To learn more about QIAGEN Biomedical KB-AI technology, visit: https://digitalinsights.qiagen.com/biomedical-knowledge-base/
About QIAGEN Digital Insights
QIAGEN Digital Insights, the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and clinicians. We have over 25 years of experience in the industry, 90,000 users worldwide, over 100,000 citations in scientific papers, more than 3.5 million profiled patient cases and over 40 billion scientific data points. Discover our portfolio of expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing and actionable insights. http://digitalinsights.qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2023, QIAGEN employed approximately 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.